Vemurafenib resistance reprograms melanoma cells towards glutamine dependence

@article{HernandezDavies2015VemurafenibRR,
  title={Vemurafenib resistance reprograms melanoma cells towards glutamine dependence},
  author={Jenny E Hernandez-Davies and Thai Q. Tran and Michael R. Reid and K. Rosales and X. Lowman and Min Pan and Gatien Moriceau and Y. Yang and J. Wu and R. Lo and M. Kong},
  journal={Journal of Translational Medicine},
  year={2015},
  volume={13}
}
  • Jenny E Hernandez-Davies, Thai Q. Tran, +8 authors M. Kong
  • Published 2015
  • Biology, Medicine
  • Journal of Translational Medicine
    • BackgroundV600BRAF mutations drive approximately 50% of metastatic melanoma which can be therapeutically targeted by BRAF inhibitors (BRAFi) and, based on resistance mechanisms, the combination of BRAF and MEK inhibitors (BRAFi + MEKi). Although the combination therapy has been shown to provide superior clinical benefits, acquired resistance is still prevalent and limits the overall survival benefits. Recent work has shown that oncogenic changes can lead to alterations in tumor cell metabolism… CONTINUE READING
    View on Springer
    translational-medicine.biomedcentral.com
    69 Citations
    Highly Influencial Citations
    1
    Background Citations
    30
    69 Citations
    Citation Type

    Citation Type

    Dependence On Glycolysis Sensitizes BRAF-mutated Melanomas For Increased Response To Targeted BRAF Inhibition
    • 34
    • PDF
    Abstract 3701: BRAF inhibitor (vemurafenib) resistance confers sensitivity to arginine deprivation in melanoma
    • PDF
    Metabolic Reprogramming in Metastatic Melanoma with Acquired Resistance to Targeted Therapies: Integrative Metabolomic and Proteomic Analysis
    • 2
    • PDF
    An Acquired Vulnerability of Drug-Resistant Melanoma with Therapeutic Potential
    • 97
    Investigating therapeutic strategies targeting metabolism in NRAS-mutant melanoma
    Melanoma Therapeutic Strategies that Select against Resistance by Exploiting MYC-Driven Evolutionary Convergence.
    • 36
    • PDF
    HI-511 overcomes melanoma drug resistance via targeting AURKB and BRAF V600E
    • 2
    • PDF
    HI-511 overcomes melanoma drug resistance via targeting AURKB and BRAF V600E
    • 1
    • PDF
    Degradation of AMPK‐α1 sensitizes BRAF inhibitor‐resistant melanoma cells to arginine deprivation
    • 4
    Melanoma Persister Cells Are Tolerant to BRAF/MEK Inhibitors via ACOX1-Mediated Fatty Acid Oxidation.
    • 1

    References

    SHOWING 1-10 OF 35 REFERENCES
    Combinatorial treatments that overcome PDGFRβ-driven resistance of melanoma cells to V600EB-RAF inhibition.
    • 194
    • PDF
    Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy.
    • 692
    • PDF
    Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032
    • 215
    • PDF
    BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies
    • 106
    • Highly Influential
    • PDF
    Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction.
    • 192
    Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
    • 1,862
    • PDF
    Emerging insights into resistance to BRAF inhibitors in melanoma.
    • 63
    Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis.
    • 175
    • PDF
    Improved survival with MEK inhibition in BRAF-mutated melanoma.
    • 1,219
    • PDF
    Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.
    • 2,112
    • PDF